Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer by Gandini, A., Martelli, V., Belgioia, L., Puglisi, S., Cremante, M., Murianni, V., Damassi, A., Pirrone, C., Catalano, F., Grassi, M., Trevisan, L., Vagge, S., Andretta, V., Mammoliti, S., Comandini, D., Fornarini, G., Pessino, A., Pastorino, A., Sciallero, S., Puccini, A., Sobrero, A.F.

Get full text

2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) by Sobrero, A.F, Price, T.J, Cervantes, A, Ducreux, M, Andre, T, Lordick, F, Punt, C.J, Hechmati, G, Demonty, G, Koukakis, R, Peeters, M

Get full text

6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard... by Sobrero, A.F, Pessino, A, Andretta, V, Bennicelli, E, Fornarini, G, Caprioni, F, Comandini, D, Orsino, L, Lambiase, A, Bordignon, C

Get full text

6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study by Rimassa, L, Santoro, A, Sobrero, A.F, Sclafani, F, Gregorc, V, Andretta, V, Tronconi, M.C, Cappio, F. Caligaris, Lambiase, A, Bordignon, C

Get full text

Does biomodulation of 5-fluorouracil improve results?: Pro by Sobrero, A.F

Get full text

Does biomodulation of 5-fluorouracil improve results? by SOBRERO, A. F, HERRMANN, R, RISCHIN, D, ZALCBERG, J

Get full text